3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
84
Lung Neoplasms
39
Carcinoma, Hepatocellular
38
Small Cell Lung Carcinoma
26
Breast Neoplasms
19
Neoplasms
18
Cholangiocarcinoma
18
Urinary Bladder Neoplasms
17
Colorectal Neoplasms
15
Triple Negative Breast Neoplasms
13
Squamous Cell Carcinoma of Head and Neck
12
Pancreatic Neoplasms
10
Liver Neoplasms
10
Biliary Tract Neoplasms
10
Recurrence
9
Ovarian Neoplasms
9
Neoplasm Metastasis
9
Esophageal Neoplasms
8
Carcinoma, Renal Cell
8
Stomach Neoplasms
7
Head and Neck Neoplasms
7
Carcinoma, Transitional Cell
7
Prostatic Neoplasms
6
Melanoma
6
Endometrial Neoplasms
6
Bile Duct Neoplasms
6
Uterine Cervical Neoplasms
5
Neoplasms by Site
5
Mesothelioma, Malignant
5
Adenocarcinoma
5
Interventions
Pemetrexed
4
pembrolizumab
3
Ramucirumab
2
Gemcitabine
2
Carboplatin
2
vistusertib
1
vandetanib
1
tusamitamab ravtansine
1
telomerase reverse transcriptase p572Y, human
1
sintilimab
1
olaparib
1
necitumumab
1
icotinib
1
durvalumab
1
dacomitinib
1
capivasertib
1
Vinorelbine
1
LY3023414
1
Injections
1
Immune Checkpoint Inhibitors
1
Erlotinib Hydrochloride
1
Drug Therapy
1
Docetaxel
1
Cisplatin
1
Bevacizumab
1
AZD4547
1
AZD 8931
1
AZD 6244
1
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Non-small Cell Lung Cancer Metastatic
×
durvalumab
×
Clear all
NCT02117167
2024-01-10
SAFIR02_Lung
UNICANCER
Phase 2
Completed
999 enrolled